These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8143220)

  • 61. [Anti-arrhythmic therapy: diagnostic possibilities of signal-averaged electrocardiography and heart rate variability].
    Tatarchenko IP; Pozdniakova NV; Shevyrev VA; Morozova OI
    Kardiologiia; 2003; 43(2):65-8. PubMed ID: 12891276
    [TBL] [Abstract][Full Text] [Related]  

  • 62. AVID necessity.
    Singer I
    Pacing Clin Electrophysiol; 1994 Feb; 17(2):260-2; author reply 262-6. PubMed ID: 7513415
    [No Abstract]   [Full Text] [Related]  

  • 63. AVID necessity.
    Epstein AE
    Pacing Clin Electrophysiol; 1993 Sep; 16(9):1773-5. PubMed ID: 7692406
    [No Abstract]   [Full Text] [Related]  

  • 64. Beta-blockade by sotalol in early myocardial infarction decreases ventricular arrhythmias without increasing left ventricular volume.
    Lloyd EA; Charles RG; Gordon GD; Adams CM; Mabin TA; Commerford PJ; Opie LH
    S Afr Med J; 1988 Jul; 74(1):5-10. PubMed ID: 3291150
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review.
    Ferreira-González I; Dos-Subirá L; Guyatt GH
    Eur Heart J; 2007 Feb; 28(4):469-77. PubMed ID: 17227788
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Emergency department management of life-threatening arrhythmias.
    Hoffman JR
    Emerg Med Clin North Am; 1986 Nov; 4(4):761-74. PubMed ID: 3536438
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Is the determination of the defibrillation threshold in patients with an implantable cardioverter-defibrillator still required?].
    Licka M; Jahn L; Kelemen K; Voss F; Trappe K; Becker R; Bikou O; Hauck M; Koch M; Katus HA; Bauer A
    Herzschrittmacherther Elektrophysiol; 2011 Dec; 22(4):209-13. PubMed ID: 22080419
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intrapericardial delivery of amiodarone and sotalol: atrial transmural drug distribution and electrophysiological effects.
    Bolderman RW; Hermans JJ; Rademakers LM; Jansen TS; Verheule S; van der Veen FH; Maessen JG
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):355-63. PubMed ID: 19701096
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sotalol versus amiodarone for postoperative junctional tachycardia after congenital heart surgery.
    Rochelson E; Valdés SO; Asadourian V; Patel R; Lemming K; Howard TS; Pham TDN; Miyake CY; Kim JJ
    Heart Rhythm; 2022 Mar; 19(3):450-456. PubMed ID: 34801734
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Concentration/response relations for the multiple antiarrhythmic actions of sotalol.
    Woosley RL; Barbey JT; Wang T; Funck-Brentano C
    Am J Cardiol; 1990 Jan; 65(2):22A-27A; discussion 35A-36A. PubMed ID: 2294688
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):3A-11A; discussion 35A-36A. PubMed ID: 2403733
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias.
    Singh BN; Sarma JS
    J Cardiovasc Pharmacol Ther; 2001 Jan; 6(1):69-87. PubMed ID: 11452339
    [No Abstract]   [Full Text] [Related]  

  • 73. Long-term experience with sotalol in the treatment of complex ventricular arrhythmias.
    Anastasiou-Nana MI; Anderson JL; Askins JC; Gilbert EM; Nanas JN; Menlove RL
    Am Heart J; 1987 Aug; 114(2):288-96. PubMed ID: 3604885
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of a pharmacist-run antiarrhythmic clinic in an ambulatory practice.
    Lifer SM; Musser MR; Kier KL
    J Am Pharm Assoc (2003); 2015; 55(5):546-51. PubMed ID: 26208334
    [TBL] [Abstract][Full Text] [Related]  

  • 75. DL and D sotalol decrease defibrillation energy requirements.
    Wang M; Dorian P
    Pacing Clin Electrophysiol; 1989 Sep; 12(9):1522-9. PubMed ID: 2476781
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias.
    Hohnloser SH; Zabel M; Krause T; Just H
    Am Heart J; 1992 May; 123(5):1220-4. PubMed ID: 1575137
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effect of sotalol on exercise-induced ventricular arrhythmias.
    Petzl DH; Probst P; Glogar D; Schuster E
    Eur Heart J; 1988 Mar; 9(3):265-70. PubMed ID: 3383867
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of intravenous sotalol on ventricular arrhythmias occurring during maximal exercise stress testing.
    Stroobandt R; Kesteloot H
    Arch Int Pharmacodyn Ther; 1983 Aug; 264(2):290-7. PubMed ID: 6639220
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Empiric use of amiodarone and sotalol.
    Nora M; Zipes DP
    Am J Cardiol; 1993 Nov; 72(16):62F-69F. PubMed ID: 8237832
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Absence of significant postdefibrillation bradyarrhythmias in patients with automatic implantable defibrillators.
    Niazi I; Kadri N; Mahmud R; Jazayeri M; Denker S; Werner P; Akhtar M; Tchou P
    Am Heart J; 1988 Apr; 115(4):830-6. PubMed ID: 3354412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.